ArticleInternational journal of chronic obstructive pulmonary disease2025
Azithromycin Mitigates Tobacco Smoke-Induced Lung Senescence by Modulating the FOXO3A/CCND1 Signaling Pathway.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A self-assembled Dendrobium polysaccharide hydrogel with anti-aging activity via the FOXO signaling pathway.Natural products and bioprospecting · 2026Article
- The Role of Cellular Senescence in Obstructive Airway Diseases: From Mechanisms to Therapeutic Targets.International journal of molecular sciences · 2026Review
- Research progress on the mechanism of FOXO protein in sepsis.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Introduction: Accelerated lung aging is observed in chronic obstructive pulmonary disease (COPD), this study delved into the precise mechanisms through which azithromycin mitigated lung aging associated with COPD. Methods: Employing network pharmacology, we predicted potential pathways through which azithromycin might affect COPD development. We collected lung tissues from non-smoking individuals, smokers with normal lung function, and smokers with COPD. COPD models were created by exposing mice to cigarette smoke (CS) for 24 weeks and stimulating human bronchial epithelial cells (BEAS-2B) with 0.2% cigarette smoke extract (CSE) for 24 hours. Azithromycin was then given to CS-exposed emphysema mice. BEAS-2B cells were pre-treated with azithromycin before being exposed to CSE and JY-2, a Forkhead box O3 (FOXO3A) inhibitor. Senescence-associated secretory phenotype (SASP) cytokines (interleukin-6, interleukin-8) in mouse BALF were quantified using ELISA. Markers associated with cellular aging (β-galactosidase activity, p53, and p21), FOXO3A, and Cyclin D1 (CCND1) were assessed via qPCR, Western blot, immunohistochemistry, and β-galactosidase staining. Results: COPD patients who smoked showed increased pulmonary expression of CCND1, p53, and p21, with decreased FOXO3A in comparison with other groups. Similarly, CS-exposed mouse lung tissue exhibited reduced FOXO3A and elevated p53, p21, and CCND1, along with higher SASP secretion in BALF. Azithromycin treatment lowered SASP secretion and decreased CCND1, p53, and p21 expression, while increasing FOXO3A. In BEAS-2B cells, CSE and JY-2 stimulation raised senescence markers and CCND1 while lowering FOXO3A. Azithromycin preconditioning reduced p53, p21, and CCND1 expression and increased FOXO3A. Conclusion: Azithromycin demonstrated anti-aging properties and modulated lung senescence in COPD via the FOXO3A/CCND1 pathway, presenting fresh insights for the treatment of COPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.